1. Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study
- Author
-
Eric Yuk Fai Wan, Colman Siu Cheung Fung, Cindy L. K. Lam, and Anca Ka Chun Chan
- Subjects
Male ,lcsh:Diseases of the circulatory (Cardiovascular) system ,Time Factors ,Kaplan-Meier Estimate ,030204 cardiovascular system & hematology ,0302 clinical medicine ,Risk Factors ,Cause of Death ,030212 general & internal medicine ,Incidence ,Mortality rate ,Hazard ratio ,Middle Aged ,All-cause mortality ,Treatment Outcome ,Cardiovascular Diseases ,Female ,lipids (amino acids, peptides, and proteins) ,Cardiology and Cardiovascular Medicine ,Cohort study ,Research Article ,medicine.medical_specialty ,Statin ,medicine.drug_class ,Subgroup analysis ,Risk Assessment ,Cardiovascular events ,03 medical and health sciences ,Asian People ,Internal medicine ,Type 2 diabetes mellitus ,medicine ,Humans ,cardiovascular diseases ,Propensity Score ,Aged ,Dyslipidemias ,Proportional Hazards Models ,Retrospective Studies ,Chi-Square Distribution ,Chinese ,Primary Health Care ,business.industry ,Type 2 Diabetes Mellitus ,nutritional and metabolic diseases ,Cholesterol, LDL ,Confidence interval ,Diabetes Mellitus, Type 2 ,lcsh:RC666-701 ,Multivariate Analysis ,Propensity score matching ,Physical therapy ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,business ,Biomarkers - Abstract
Background The benefit of statin on the management of Type 2 Diabetes Mellitus (T2DM) among Chinese patients in primary care is not clear nor fully implemented in clinical practice. This study aimed to evaluate and quantify the benefit of statin on the overall cardiovascular risk and all-cause mortality in patients with T2DM. Methods Uncomplicated diabetic patients with baseline low-density-lipoprotein cholesterol (LDL-C) > 2.6 mmol/L and without statin use before baseline in 2010 were followed-up for 5 years for cardiovascular disease (CVD) events and all-cause mortality. Propensity score matching analysis was conducted to identify patients who were newly prescribed statin at baseline and then compared to non-statin users with similar baseline characteristics. Subgroup analysis was done within the statin group to detect any difference in outcomes between patients achieving target LDL-C of
- Published
- 2017
- Full Text
- View/download PDF